While this is a widespread finding in patients exhibiting successful tumor responses following immunotherapy with CTLA4-specific with or without PD1-specific antibodies, adverse inflammatory effects are not commonly found in mice treated in a similar way. Here, CTLA4 is linked to neoplasm.